Rohto Pharmaceutical Co.,Ltd. (TYO:4527)
2,178.50
-263.00 (-10.77%)
May 14, 2025, 3:30 PM JST
Rohto Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 77,161 | 89,210 | 79,951 | 72,791 | 52,964 | Upgrade
|
Cash & Short-Term Investments | 77,161 | 89,210 | 79,951 | 72,791 | 52,964 | Upgrade
|
Cash Growth | -13.51% | 11.58% | 9.84% | 37.44% | 16.90% | Upgrade
|
Receivables | 69,880 | 69,115 | 60,656 | 51,682 | 47,865 | Upgrade
|
Inventory | 61,580 | 46,657 | 41,062 | 33,527 | 27,925 | Upgrade
|
Other Current Assets | 9,258 | 9,777 | 8,577 | 6,306 | 4,317 | Upgrade
|
Total Current Assets | 217,879 | 214,759 | 190,246 | 164,306 | 133,071 | Upgrade
|
Property, Plant & Equipment | 90,451 | 68,607 | 66,182 | 62,839 | 49,790 | Upgrade
|
Long-Term Investments | 46,649 | 43,731 | 32,629 | 27,471 | 27,425 | Upgrade
|
Goodwill | 47,494 | 2,285 | 2,564 | 2,954 | 4,014 | Upgrade
|
Other Intangible Assets | 8,575 | 6,932 | 6,997 | 6,338 | 3,521 | Upgrade
|
Long-Term Deferred Tax Assets | 3,975 | 3,869 | 5,371 | 5,297 | 4,606 | Upgrade
|
Long-Term Deferred Charges | 99 | - | - | - | - | Upgrade
|
Other Long-Term Assets | 2 | 2 | 1 | 2 | 2 | Upgrade
|
Total Assets | 421,875 | 346,175 | 309,677 | 274,627 | 225,790 | Upgrade
|
Accounts Payable | 22,056 | 21,123 | 18,718 | 16,269 | 11,330 | Upgrade
|
Accrued Expenses | 24,364 | 25,720 | 24,362 | 19,354 | 25,208 | Upgrade
|
Short-Term Debt | 7,035 | 5,304 | 4,177 | 8,033 | 2,312 | Upgrade
|
Current Income Taxes Payable | 6,963 | 6,643 | 6,230 | 3,185 | 6,138 | Upgrade
|
Other Current Liabilities | 34,190 | 28,297 | 26,675 | 24,647 | 11,483 | Upgrade
|
Total Current Liabilities | 94,608 | 87,087 | 80,162 | 71,488 | 56,471 | Upgrade
|
Long-Term Debt | 43,188 | 5,190 | 7,516 | 13,350 | 5,787 | Upgrade
|
Long-Term Deferred Tax Liabilities | 2,081 | 1,597 | 1,173 | 1,450 | 639 | Upgrade
|
Other Long-Term Liabilities | 8,789 | 2,720 | 2,645 | 1,177 | 2,831 | Upgrade
|
Total Liabilities | 150,436 | 99,142 | 94,600 | 90,797 | 69,179 | Upgrade
|
Common Stock | 6,504 | 6,504 | 6,504 | 6,504 | 6,504 | Upgrade
|
Additional Paid-In Capital | - | 4,516 | 5,292 | 5,787 | 5,661 | Upgrade
|
Retained Earnings | 228,442 | 209,399 | 184,005 | 162,195 | 145,511 | Upgrade
|
Treasury Stock | -9,939 | -4,939 | -4,938 | -4,936 | -4,936 | Upgrade
|
Comprehensive Income & Other | 35,087 | 30,843 | 18,706 | 8,737 | 3,167 | Upgrade
|
Total Common Equity | 260,094 | 246,323 | 209,569 | 178,287 | 155,907 | Upgrade
|
Minority Interest | 11,345 | 710 | 5,508 | 5,543 | 704 | Upgrade
|
Shareholders' Equity | 271,439 | 247,033 | 215,077 | 183,830 | 156,611 | Upgrade
|
Total Liabilities & Equity | 421,875 | 346,175 | 309,677 | 274,627 | 225,790 | Upgrade
|
Total Debt | 50,223 | 10,494 | 11,693 | 21,383 | 8,099 | Upgrade
|
Net Cash (Debt) | 26,938 | 78,716 | 68,258 | 51,408 | 44,865 | Upgrade
|
Net Cash Growth | -65.78% | 15.32% | 32.78% | 14.58% | 18.03% | Upgrade
|
Net Cash Per Share | 117.67 | 344.04 | 298.33 | 224.69 | 196.09 | Upgrade
|
Filing Date Shares Outstanding | 226.8 | 228.14 | 228.14 | 228.14 | 228.14 | Upgrade
|
Total Common Shares Outstanding | 226.8 | 228.14 | 228.14 | 228.14 | 228.14 | Upgrade
|
Working Capital | 123,271 | 127,672 | 110,084 | 92,818 | 76,600 | Upgrade
|
Book Value Per Share | 1146.80 | 1079.71 | 918.60 | 781.48 | 683.38 | Upgrade
|
Tangible Book Value | 204,025 | 237,106 | 200,008 | 168,995 | 148,372 | Upgrade
|
Tangible Book Value Per Share | 899.58 | 1039.31 | 876.69 | 740.75 | 650.35 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.